field beam

GenesisCare signs AUD$132 million strategic partnership with Sweden’s Elekta AB

Australia’s largest cancer and cardiac services organisation, GenesisCare, has today announced the formation of a multi-year strategic partnership with Swedish medical equipment manufacturer, Elekta AB.

The partnership, initially over eight years, will include order bookings valued at more than AUD$132 million (USD$100 million).

GenesisCare Managing Director, Dan Collins, said: “Our ambition is to transform health care and improve outcomes for cancer patients around the world by improving access to high quality care. This is facilitated by the coordination of enterprise-wide practices and enhanced cancer management technology available for use by our committed and highly skilled medical teams.

“The suite of technology solutions, global reach and commitment to innovation offered by Elekta helps us to achieve a better result for patients.”

The partnership includes the acquisition of solutions across Elekta’s portfolio, including Leksell Gamma Knife® Icon™ radiosurgery systems, Versa HD™ linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centres in Australia, the UK and new international markets.

GenesisCare is also expected to order Elekta’s high-field (1.5 Tesla) MRI-guided linear accelerator (MR-linac*) when this new treatment technology is available in the market in 2017.

“The MR-linac is a game changer. We expect it will improve the accuracy of treatment and provide a smoother patient experience which should improve outcomes. We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation,” said Mr Collins.

Of the partnership, Tomas Puusepp, President and CEO of Elekta said: “We are proud to partner alongside GenesisCare and support their exciting vision. GenesisCare will receive the most advanced and recognised cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme accuracy, efficiency and outstanding outcomes. We are looking forward to being GenesisCare’s partner as they expand into new markets.”

Software systems included in the agreement comprise Elekta’s MOSAIQ® enterprise licensing, which provides a full-featured OIS to enable a completely optimized, automated workflow across their entire global enterprise – to fulfill the organization’s “Cancer Services of the Future” vision. The deal also includes METRIQ®, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.

*Elekta’s MR-linac is a works in progress and not yet available for sale or distribution in Australia or the UK.

For further information, please contact:
Dan Collins, Managing Director, GenesisCare
Tel: 02 8236 3388, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Nigel Kassulke, Director, Cannings Corporate Communications
Tel: 02 8284 9905, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

About GenesisCare

GenesisCare provides high quality specialist care to patients with cancer and cardiovascular disease, the two largest disease burdens globally. The organisation exists to improve quality and access for patients and communities in need. The Group is the largest provider of radiotherapy across Australia, operating 25 cancer centres in major metropolitan and also regional settings (including in tertiary teaching public hospitals). More than 80 locations provide cardiology or sleep services. GenesisCare employs more than 1700 highly trained health professionals and support staff including more than 150 physicians and leads or participates in more than 100 clinical trials.

Cancer care is provided for all tumor groups with the latest techniques including intensity modulated radiotherapy, volumetric arc therapy, stereotactic radiotherapy and radiosurgery, low dose rate and high dose rate brachytherapy.

The GenesisCare medical team comprises some of the world’s most experienced specialists with many dedicating time as consultants in public hospitals or participating in research and teaching. GenesisCare is adopting internationally proven medical technologies integrated with electronic healthcare records to improve patient clinical outcomes and their service experience.

In July 2015 GenesisCare acquired the United Kingdom’s leading provider of private cancer services, Cancer Partners UK. Having recently opened a new cancer treatment centre in Kings Hill, the renamed GenesisCare UK now operates ten clinics, undertaking overflow support for three National Health Service Trust hospitals. GenesisCare UK plans to open the first of two cancer centres with Ramsay Hospitals UK commencing at Springfield (Essex) in August with a further two cancer centres expected to open in 2017.

Website: www.genesiscare.com.au

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm.

Website: www.elekta.com

Download the media release in PDF format

Genesis Logo Small.png

GenesisCare is largest provider of radiation oncology in Australia, the UK and Spain, and also the leading provider of cardiology and sleep treatments in Australia. We exist to fill the treatment gap for the biggest disease burdens – cancer and heart disease – in an environment of substantial unmet demand from an ageing population. Click here to learn more